Evidence map›Paper›PMID 31759361›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2019

The Synergistic Cytotoxic Effect of Laser-Irradiated Gold Nanoparticles and Sorafenib Against the Growth of a Human Hepatocellular Carcinoma Cell Line.

Haidy M Ebrahim, Mahmoud N El-Rouby, Mona E Morsy, Mahmoud M Said, Magda K Ezz

Abstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Haidy M EbrahimDepartment of Cancer Biology, National Cancer Institute (NCI), Cairo University, Giza, Egypt.ORCID 0000-0003-0804-1512
Mahmoud N El-RoubyDepartment of Cancer Biology, National Cancer Institute (NCI), Cairo University, Giza, Egypt.
Mona E MorsyDepartment of Medical Applications, National Institute of Laser-Enhanced Science, Cairo University, Giza, Egypt.
Mahmoud M SaidDepartment of Biochemistry, Faculty of Science, Ain Shams University, Cairo, Egypt.ORCID 0000-0003-3599-3383
Magda K EzzDepartment of Biochemistry, Faculty of Science, Ain Shams University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gold nanoparticles are the most promising candidate in cancer treatment due to their physiochemical properties<br /> and increased use in photothermal therapy (PTT). In the present study, spherical gold nanoparticles (AuNPs) were<br /> synthesized using citrate reduction method. The particles were then characterized using UV-VIS spectroscopy and<br /> transmission electron microscope. A hepatocellular carcinoma cell line (HepG2) was incubated with sorafenib and/or<br /> non-irradiated or laser-irradiated AuNPs for 48 hrs. The cytotoxic effect of different treatment modalities was determined<br /> using MTT assay. Furthermore, apoptosis was determined by flow cytometry using annexin V/propidium iodide, as<br /> well as estimating the level of caspases. Results showed that AuNPs and sorafenib reduced HepG2 cell viability, and<br /> the cytotoxicity was associated with increased release of LDH in the culture medium. The recorded cytotoxicity was<br /> attributed to enhanced apoptosis as revealed by increased cellular caspases (3, 8 and 9), that was further confirmed by<br /> flow cytometry. The most notable cytotoxic effect was recorded when combining sorafenib with laser-irradiated AuNPs.<br /> In conclusion, a synergistic cytotoxic effect was observed between sorafenib and laser-irradiated AuNPs against the<br /> growth of HepG2, suggesting the potential substitution of large toxic doses of sorafenib by lower doses in combination<br /> with photothermal therapy.

Indexed as

Antineoplastic AgentsApoptosisCarcinoma, HepatocellularCaspasesCell Line, TumorCell ProliferationCell SurvivalDrug SynergismGoldHep G2 CellsHumansLiver NeoplasmsMetal NanoparticlesSorafenibAntineoplastic AgentsCaspasesGoldSorafenibGold NanoparticlesHepatocellular carcinomaphotothermal therapysorafenib

Identifiers

PMID31759361
PMCPMC7062997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.